These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16582518)

  • 1. [Bisphosphonates for bone metastasis of malignant tumor].
    Kaise H; Kohno N
    Clin Calcium; 2006 Apr; 16(4):655- 64. PubMed ID: 16582518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of bisphosphonates for bone pain control].
    Yamada K; Kohno N
    Nihon Rinsho; 2007 Jan; 65(1):152-6. PubMed ID: 17233431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bisphosphonates on pain and quality of life in patients with bone metastases.
    Costa L; Major PP
    Nat Clin Pract Oncol; 2009 Mar; 6(3):163-74. PubMed ID: 19190592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
    Kostenuik PJ
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in the biology and treatment of myeloma bone disease.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 17):11-6. PubMed ID: 12520479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
    Costa L
    Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of bone disease.
    Kinnane N
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S28-31. PubMed ID: 17768092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
    Rosen LS
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative Oncology: Denosumab.
    Prommer E
    Am J Hosp Palliat Care; 2015 Aug; 32(5):568-72. PubMed ID: 24928835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
    Anghel R; Bachmann A; Bekşac M; Brodowicz T; Finek J; Komadina R; Krzemieniecki K; Lang I; Marencak J; von Moos R; Pecherstorfer M; Rordorf T; Vrbanec D; Zielinski C; ;
    Wien Klin Wochenschr; 2013 Aug; 125(15-16):439-47. PubMed ID: 23832237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of metastatic bone disease in the elderly with bisphosphonates and receptor activator of NF-kB ligand inhibitors: effectiveness and safety.
    Vassiliou V
    Clin Oncol (R Coll Radiol); 2013 May; 25(5):290-7. PubMed ID: 23466465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of bisphosphonates on pain relief in patients with bone metastases: A status article based on the Cochrane analysis: "Bisphosphonates for the relief of pain secondary to bone metastasis"].
    Ejlertsen B; Kristensen B
    Ugeskr Laeger; 2003 May; 165(20):2089-91. PubMed ID: 12812098
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
    Berenson JR; Vescio RA; Rosen LS; VonTeichert JM; Woo M; Swift R; Savage A; Givant E; Hupkes M; Harvey H; Lipton A
    Clin Cancer Res; 2001 Mar; 7(3):478-85. PubMed ID: 11297237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
    Saba N; Khuri F
    Oncology; 2005; 68(1):18-22. PubMed ID: 15775689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].
    Kamoto T
    Clin Calcium; 2011 Mar; 21(3):465-71. PubMed ID: 21358069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.